

CLAIMS

1. Use of nefopam for the manufacture of a medicament for use in the treatment of a condition selected from nausea, dizziness, blurred vision and emesis.
- 5 2. Use according to claim 1, wherein the condition is acute, delayed, post-operative, late-phase or anticipatory emesis.
3. Use according to claim 1 or claim 2, wherein the condition is associated with dysmenorrhoea, migraine, cancer or other pain condition.
4. Use according to claim 1 or claim 2, wherein the condition is induced by
10 one or more of radiation, toxins, pregnancy, alcohol withdrawal, nicotine withdrawal, drug withdrawal, vestibular disorder, motion, post-operative sickness, surgery, gastrointestinal obstruction, reduced gastrointestinal mobility, visceral pain or increased or decreased intracranial pressure.
5. Use according to any preceding claim, wherein the condition is drug-
15 induced.
6. Use according to claim 5, wherein the condition is induced by chemotherapy.
7. Use according to claim 5 wherein the condition is induced by an opioid analgesic.
- 20 8. Use according to any preceding claim, wherein the patient is also administered another agent that has anti-emetic properties.
9. Use according to claim 8, wherein said agent is selected from phenothiazines, 5HT₃ receptor antagonists, dopamine antagonists, anticholinergic agents, anti-histamines, histamine analogues, cannabinoids,
25 corticosteroids, GABA receptor antagonists, NK₁ receptor antagonists, and α_2 and α_3 adrenoceptor antagonists.
10. Use according to claim 8, wherein said agent is selected from cyclizine, dolasetron, granisetron, ondansetron, tropisetron, nabilone, scopolamine, cinnarizine, promethazine, betahistine, dexamethasone, methylprednisolone,
30 metoclopramide, chlorpromazine, perphenazine, prochlorperazine, thiethylperazine, droperidol, domperidone and haloperidol.